Sotsiaalministeerium · 11. detsember 2018
Sisu (failidest)
EJP RD JTC 2019: MoU
European Joint Programme on Rare Diseases
(EJP RD)
Call for Proposals 2019
"Transnational research projects to accelerate diagnosis and/or explore
disease progression and mechanisms of rare diseases”
Memorandum of Understanding (MoU) on
International Cooperation in Research Funding
within the Framework of the EJP on Rare Diseases
JTC 2019
Established between the following Parties
Austrian Science Fund (FWF), Austria
Research Foundation Flanders (FWO), Belgium, Flanders
Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium, Wallonia
Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
Ministry of Education, Youth and Sports (MEYS), Czech Republic
Ministry of Social Affairs of Estonia (MoSAE), Estonia
Academy of Finland (AKA), Finland
French National Research Agency (ANR), France
French Foundation for Rare Diseases (FFRD), France
Federal Ministry of Education and Research (BMBF), Germany
German Research Foundation (DFG), Germany
General Secretariat for Research and Technology (GSRT), Greece
National Research, Development and Innovation Office (NKFIH), Hungary
Health Research Board, (HRB), Ireland
Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
Italian Ministry of Health (MoH-IT), Italy
Ministry of Education, Universities and Research (MIUR), Italy
Regional Foundation for Biomedical Research (FRRB), Lombardy (Italy)
Tuscany Region (RT/TuscReg), Tuscany (Italy)
Research Council of Lithuania (RCL), Lithuania
National Research Fund (FNR), Luxembourg
National Centre for Research and Development (NCBR), Poland
The Foundation for Science and Technology (FCT), Portugal
Slovak Academy of Sciences (SAS), Slovakia
National Institute of Health Carlos III (ISCIII), Spain
Swedish Research Council (SRC), Sweden
Vinnova, Sweden
EJP RD JTC 2019: MoU
Swiss National Science Foundation (SNSF), Switzerland
Netherlands Organization for Health Research and Development (ZonMw), The
Netherlands
The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey
The French National Institute of Health and Medical Research (INSERM), France (will
provide dedicated funding only to Patient Advocacy Organisations)
EJP RD JTC 2019: MoU
PREAMBLE
There are at least 7000 distinct rare diseases, the great majority being of genetic origin.
Although individually rare, taken together rare diseases affect at least 26-30 million people in
Europe. Moreover, they represent a major issue in health care: a large number of these
diseases have an early or very early onset and/or lead to a significant decrease of life
expectancy. Moreover, most of them cause chronic illnesses with a large impact on quality of
life and the health care system.
Therefore, research on rare diseases is needed to provide knowledge for prevention,
diagnosis and better care of patients. Yet, research is hampered by lack of resources at
several levels: (1) Few scientists work on any given specific disease, (2) There are few
patients per disease and they are scattered over large geographic areas, causing difficulties
to assemble the necessary cohorts, (3) Existing databases and bio-material collections are
usually local, small, and not accessible or standardised, (4) The complex clinical phenotypes
of these diseases require interdisciplinary cooperation to improve research and treatment.
In this context, the ERA-Net E-Rare has successfully implemented ten Joint Transnational
Calls for rare disease research projects since 2006. This effort is now continued in the frame
of the European Joint Programme on Rare Diseases (EJP RD) that has been established to
further help in coordinating the research efforts of European, Associated and non-European
countries in the field of rare diseases and implement the objectives of the International Rare
Disease Research Consortium (IRDiRC).
Under the umbrella of the EJP RD the above listed Parties decided to open the joint call for
funding multilateral research projects on rare diseases (JTC 2019).
This Memorandum of Understanding (MoU) is a mutual statement of intention among the
Parties. It serves to document the commitment of the Parties who agree to make every
reasonable effort to fulfil the intents expressed in this joint call as well as the intended
financial framework.
The aim of this Memorandum of Understanding (MoU) is to establish the principles and
procedures to be adopted by all Parties in the Joint Transnational Call JTC 2019:
Launching a common call for proposals
Receiving collaborative proposals
Setting up a common evaluation and selection procedure
Providing funding for the proposals selected according to the final ranking list
For each Party, the MoU will come into force on the date of signature by the Party’s
authorized representative and shall remain in force until the end of submission of the final
report of the funded projects. The MoU may be amended or modified by written agreement of
all signatories or their authorized representatives.
Details on the implementation of the joint call are outlined in the document “Governance of
the call and evaluation procedure”.
The Parties agree as follows.
EJP RD JTC 2019: MoU
1. CONTENT OF THE CALL
It is hereby agreed that the Parties shall launch a transnational programme "Transnational
research projects to accelerate diagnosis and/or explore disease progression and
mechanisms of rare diseases" which will be jointly managed and financed by the
participating organisations that are members of the EJP RD, according to their respective
legal framework and regulations. The programme will be implemented by a call for proposals
to be launched and processed in 2019-2020. The call will be opened simultaneously by the
Parties in their respective countries and regions.
2. GOVERNANCE OF THE CALL AND EVALUATION PROCEDURE
The governance of the call, its organization and the evaluation procedures are detailed in the
document “Governance of the call and evaluation procedure”.
All decisions concerning the JTC 2019 call procedures and transnational project funding will
be taken by the Call Steering Committee (CSC) together with the European Commission.
The Joint Call Secretariat (JCS) of JTC 2019 will be organized by DLR-PT, Germany. The
responsibilities of the CSC and the JCS are detailed in the document “Governance of the call
and evaluation procedure”. The scientific assessment of applications will be undertaken by a
Scientific Evaluation Committee (SEC) on the basis of scientific quality and evaluation criteria
as specified in the document “Governance of the call and evaluation procedure”. The CSC
will select proposals for funding according to the reviews and the final ranking list established
by the SEC. Subsequently the final decision will be made by the respective national/regional
funding organisations.
A two-stage submission/evaluation procedure for joint proposals with a rebuttal stage shall
be applied.
3. ELIGIBILITY OF APPLICATIONS
The eligibility of institutions, researchers, patient organisations and costs, as well as
complementary administrative requirements are subject to the country/regional Party’s
regulations and legal framework and may therefore vary from one Party to another.
Information needs to be provided in time and form according to relevant Party’s regulations
for research funding. The general eligibility rules for this call are specified in the call text and
the national/regional criteria in the guidelines document.
4. FUNDING BUDGETS AND PROCEDURES
The intended contribution by each participating organisation is listed below.
Envisioned
amount of
Country/Region Participating organisation
funding (M€ for
3 years)
Austria FWF 0.6
EJP RD JTC 2019: MoU
Belgium/Flanders FWO 0.7
Belgium/French speaking
F.R.S.-FNRS 0.24
community
Canada CIHR-IG 1 1.0
Canada FRQS 0.33
Czech Republic MEYS 0.6
Estonia MoSAE 0.075
Finland AKA 0.6
France ANR 3.0
France FFRD 0.1
Germany BMBF 3.0
Germany DFG 3.0
Greece GSRT 1.0
Hungary NKFIH 0.2
Israel CSO/MOH 0.3
Ireland HRB 0.37
Italy MoH-IT 2.0
Italy MIUR 0.4
Italy FRRB 1.3
Italy RT/TuscReg 0.3
Lithuania RCL 0.1
Luxembourg FNR 0.3
Poland NCBR 0.6
Portugal FCT 0.3
Slovakia SAS 0.12
Spain ISCIII 0.5
1
CIHR-IG will fund to a maximum of $1.5 million Canadian over three years (currently equivalent to 1 Mio €) to support
operational research costs only. The Canadian amount will not be adjusted to reflect conversion rate changes.
EJP RD JTC 2019: MoU
Switzerland SNSF2 0.84
Sweden SRC 1.5
Sweden Vinnova 1.0
The Netherlands ZonMw3 1.8
Turkey TUBITAK 1.0
Multinational, funding for PAO INSERM 0.5
The funds provided by the Parties to this MoU (table above) will be used for research
projects carried out by research partners and institutions according to their respective
countries’ regulations and legal framework and based on the scientific quality of the
proposals reflected by the SEC evaluation decision.
As far as possible, the proposals will be funded in accordance with the ranking order as a
result of the SEC advice, starting with the top-scoring proposals. In order to avoid early
funding gaps, each funding organization participating in the joint call is asked to match as
accurately and realistically as possible the financial demand from the proposals with the
budget earmarked for the call. The final decision on funding will be taken by the respective
national/regional funding organizations involved in the application. The respective
national/regional funding organization will decide upon the information provided by the CSC
after recommendations from the SEC. Selected projects will receive funding directly from the
corresponding national/regional funding organizations according to their respective policies
and guidelines.
Funding will be awarded and administered according to the terms and conditions of
responsible national/regional funding organizations taking into account all other applicable
national/regional regulations and legal framework.
5. REPORTING
The coordinators of all funded projects must submit brief annual scientific project reports and
a final scientific project report in the form of an online questionnaire. This monitoring will be
under the responsibility of CSH-MOH, Israel, and FNRS, Belgium, which is responsible for
the online monitoring system for the funded projects
In addition, each team may have to report to its funding organisation, in accordance with the
respective national/regional funding organisations’ regulations.
6. MISCELLANEOUS
The MoU shall become effective by the signatures of the Parties on the date given below. It
shall cover the entire funding period of the joint call research projects at least until all
2
SNSF has earmarked a budget of 1.0 million Swiss Francs over three years (currently equivalent to 0.84 Mio €).
3
Maximum funding of 250,000 € for Dutch participation per project
EJP RD JTC 2019: MoU
agreements are settled (expected to start early in 2020 and to last at least 3 years), except
force majeure, and including any extension period to be specified later.
This MoU represents the intentions of the Parties, made in good faith, to collaborate in
respect of the joint transnational call for research projects on rare diseases. Each Party
hereto understands and agrees that nothing contained in this MoU is intended to constitute a
legally binding obligation.
The undersigned funding organizations, participants of EJP RD, have agreed to issue a joint
call at the end of 2018, in accordance with the documents developed for these activities, in
each country/region, including:
Call text
Governance of the call and evaluation procedure
Guidelines for applicants
Pre-proposal application form
Full proposal application form
7. SIGNATURES
EJP RD JTC 2019: MoU
For Austrian Science Fund (FWF), Austria
NAME: Prof. KLEMENT TOCKNER
POSITION: President of FWF
Signature:
Date:
EJP RD JTC 2019: MoU
For Research Foundation - Flanders (FWO), Flanders, Belgium
NAME: Dr. Hans Willems
POSITION: Secretary General
Signatures:
Date:
EJP RD JTC 2019: MoU
Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium
NAME: Dr. ir. Véronique Halloin
POSITION: Secretary General
Signature:
Date:
EJP RD JTC 2019: MoU
For Canadian Institutes of Health Research Institute of Genetics (CIHR-IG)
NAME: Dr. Michael Strong
POSITION: Scientific Director, CIHR Institute of Genetics
Signature:
Date:
EJP RD JTC 2019: MoU
For Fonds de Recherche du Québec-Santé (FRQS), Québec (Canada)
NAME: Dr. Serge Marchand
POSITION: Scientific Director, Fonds de recherche du Québec-Santé (FRQS)
Signature:
Date:
EJP RD JTC 2019: MoU
For Ministry of Education, Youth and Sports (MEYS), Czech Republic
NAME: PhDr. Pavel Doleček, Ph.D.
POSITION: Deputy Minister, Research and Higher Education section
Signature:
Date:
EJP RD JTC 2019: MoU
For Ministry of Social Affairs of Estonia (MoSAE), Estonia
NAME: Marika Priske
POSITION: Secretary General
Signature:
Date:
EJP RD JTC 2019: MoU
For Academy of Finland (AKA), Finland
NAME: Dr. Riitta Maijala
POSITION: Vice President, research
Signature:
Date:
EJP RD JTC 2019: MoU
For French National Research Agency (ANR), France
NAME: Thierry Damerval
POSITION: Président Directeur Général
Signature:
Date:
EJP RD JTC 2019: MoU
For French Foundation for Rare Diseases (FFRD), France
NAME: Daniel Scherman
POSITION: Director
Signature:
Date:
EJP RD JTC 2019: MoU
For Federal Ministry of Education and Research (BMBF), Germany
NAME: Dr. Renate Loskill
POSITION: Head of department
Signature:
Date:
EJP RD JTC 2019: MoU
For German Research Foundation (DFG), Germany
NAME: Dr. Annette Schmidtmann
POSITION: Head of Department for Scientific Affairs
Signature:
Date:
EJP RD JTC 2019: MoU
For General Secretariat for Research and Technology (GSRT), Greece
NAME: Dr. Patricia Kyprianidou
POSITION: Secretary General for Research and Technology
Signature:
Date:
EJP RD JTC 2019: MoU
For National Research, Development and Innovation Office (NKFIH), Hungary
NAME: Dr. József Pálinkás
POSITION: President
Signature:
Date:
EJP RD JTC 2019: MoU
For Health Research Board, (HRB), Ireland
NAME Dr. Mairead O’Driscoll
POSITION: Director of research Strategy and Funding
Signature:
Date:
EJP RD JTC 2019: MoU
For the Chief Scientist Office, Ministry of Health (CSO-MOH), Israel
NAME Prof. Avi Israeli
POSITION: Chief Scientist of the Ministry of Health
Signature:
Date:
EJP RD JTC 2019: MoU
For Ministry of Health – Ministero della Salute (MOH-IT), Italy
NAME: Dr. Giselda Scalera
POSITION: Head Office 5 (Health Research IRCCS), Directorate General for Research and
Innovation in Healthcare, Ministry of Health
Signature:
Date:
EJP RD JTC 2019: MoU
For Ministry of Education, Universities and Research (MIUR), Italy
NAME: Dr. Vincenzo Di Felice
POSITION: Director General
Signature:
Date:
EJP RD JTC 2019: MoU
For Regional Foundation for Biomedical Research (FRRB), Lombardy (Italy)
NAME: Marina Gerini
POSITION: General Director
Signature:
Date:
EJP RD JTC 2019: MoU
For Tuscany Region (RT/TuscReg), Tuscany (Italy)
NAME: Katia Belvedere
POSITION: Head of Office, Legal advice, administrative support to research and clinical
governance bodies, Directorate for citizenship right and social cohesion, Tuscany
Region
Signature:
Date:
EJP RD JTC 2019: MoU
For Research Council of Lithuania (RCL), Lithuania
NAME: Valdemaras Razumas
POSITION: Chairman of the Research Council of Lithuania
Signature:
Date:
EJP RD JTC 2019: MoU
For National Research Fund (FNR), Luxembourg
NAME: Prof. Dr. Marc Schiltz
POSITION: Secretary General
Signature:
Date:
EJP RD JTC 2019: MoU
For National Centre for Research and Development (NCBR), Poland
NAME: Prof. Maciej Chorowski
POSITION: Director
Signature:
Date:
EJP RD JTC 2019: MoU
For The Foundation for Science and Technology (FCT), Portugal
NAME: Paulo Ferrão
POSITION: President
Signature:
Date:
EJP RD JTC 2019: MoU
For Slovak Academy of Sciences (SAS), Slovakia
NAME: Prof. Pavol ŠAJGALÍK
POSITION: President
Signature:
Date:
EJP RD JTC 2019: MoU
For National Institute of Health Carlos III Instituto de Salud Carlos III (ISCIII)] Spain
NAME: Dra. Raquel Yotti Álvarez
POSITION: Director General
Signature:
Date:
EJP RD JTC 2019: MoU
For Swedish Research Council (SRC), Sweden
NAME: Sven Stafström
POSITION: Director General, The Swedish Research Council
Signature:
Date:
EJP RD JTC 2019: MoU
For Vinnova, Sweden
NAME: Darja Isaksson
POSITION: Director General for Vinnova
Signature:
Date:
EJP RD JTC 2019: MoU
For Swiss National Science Foundation (SNSF)
NAME: Dr. Ayșim Yılmaz
POSITION: Head, Division Biology and Medicine, Swiss National Science Foundation
Signature:
Date:
EJP RD JTC 2019: MoU
The Netherlands Organisation for Health Research and Development (ZonMw), The
Netherlands
NAME: Dr. Martijntje Bakker
POSITION: Co-director ZonMw
Signature:
Date:
EJP RD JTC 2019: MoU
For The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey
NAME: Prof. Dr. Hasan Mandal
POSITION: President
Signature:
Date:
EJP RD JTC 2019: MoU
ANNEX: EJP RD JTC 2019 Call Steering Committee (CSC) composition
Austrian Science Fund (FWF), Austria
Representative
Name: Dr. Stephanie Resch
Position: Scientific officer
Proxy
Name: Anita Stuertz, Dipl.-Ing.
Position: Operational Project Officer
Research Foundation - Flanders (FWO), Flanders, Belgium
Representative
Name: Alain Deleener
Position: Science Policy Advisor Strategic Research Programmes
Proxy
Name: Toon Monbaliu
Position: Advisor Research Affairs
Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium
Representative
Name: Florence Quist
Position: Scientific officer
Proxy
Name: Joël Groeneveld
Position: Policy officer
Canadian Institutes of Health Research (CIHR-IG), Canada
Representative
Name: Maxime Beaudoin
Position:
Proxy
Name: Marilyn Desrosiers
Position: Deputy Director, Strategic Program Design and Analytics, CIHR
Fonds de Recherche du Québec-Santé (FRQS), Québec (Canada)
EJP RD JTC 2019: MoU
Representative
Name: Sylvain Charbonneau
Position: Director, Programs and Partnerships, FRQS
Proxy
Name: Maxime Beaudoin
Position: Program Manager, FRQS
Ministry of Education, Youth and Sports (MEYS), Czech Republic
Representative
Name: Mgr. Daniel Hanšpach
Position: Officer
Proxy
Name: Mgr. Monika Kocmanová
Position: Head of Unit of the European Research Area
Ministry of Social Affairs of Estonia (MoSAE), Estonia
Representative
Name: Heli Paluste
Position: Head of Health Care Unit
Proxy
Name: Angela Ivask
Position: Scientific Adviser for Health Policy
Academy of Finland (AKA), Finland
Representative
Name: Heikki Vilen
Position: Science adviser
Proxy
Name: Antti Hautaniemi
Position: Science Adviser
French National Research Agency (ANR), France
Representative
Name: Dr. Daria Julkowska
Position: Scientific Coordinator
EJP RD JTC 2019: MoU
Proxy
Name: Dr. Florence Guillot
Position: Scientific Officer
French Foundation for Rare Diseases (FFRD), France
Representative
Name: Daniel Scherman
Position:
Proxy
Name: Ingrid Zwaenepool
Position:
Federal Ministry of Education and Research (BMBF), Germany
Representative
Name: Dr. Ralph Schuster
Position: Scientific officer
Proxy
Name: Dr. Katarzyna Saedler
Position: Scientific officer
Name: Dr. Michaela Fersch
Position: Scientific officer
German Research Foundation (DFG), Germany
Representative
Name: Dr. Katja Grossmann
Position: Programme Officer
Proxy
Name: Dr. Theodora Hogenkamp
Position: Programme Director
General Secretariat for Research and Technology (GSRT), Greece
Representative
Name: Sofia Dimitropoulou
Position: Programme Officer
EJP RD JTC 2019: MoU
National Research, Development and Innovation Office (NKFIH), Hungary
Representative
Name: Dr. Gábor Tóth
Position: Department of Research and Development
Proxy
Name: Dr. Előd Nemerkényi
Position: Assistant of International Affairs
Health Research Board (HRB), Ireland
Representative
Name: Annalisa Montesanti PhD
Position: Programme Manager
Chief Scientist Office, Ministry of Health (CSO-MOH), Israel
Representative
Name: Prof. Avi Israeli
Position: Chief Scientist
Proxy
Name: Dr. Irit Allon
Position:
Ministry of Health – Ministero della Salute (MOH), Italy
Representative
Name: Dr. Giselda Scalera
Position: Head Office 5 (Health Research IRCCS)
Proxy
Name: Dr. Raffaele Ruocco
Position:
Ministry of Education, Universities and Research (MIUR), Italy
Representative
Name: Aldo Covello
Position:
Proxy
Name: Valeria Cardia
EJP RD JTC 2019: MoU
Position:
Regional Foundation for Biomedical Research (FRRB), Lombardy (Italy)
Representative
Name: Marina Gerini
Position: General Director
Proxy
Name: Paola Bello
Position: EU Funding officer
Tuscany Region (RT/TuscReg), Tuscany (Italy)
Representative
Name: Donatella Tanini
Position:
Proxy
Name: Teresa Vieri
Position:
Research Council of Lithuania (RCL), Lithuania
Representative
Name: Živilė Ružele
Position Chief Officer
Proxy
Name: Jūratė Devižienė
Position: Head of International Programmes Unit
National Research Fund (FNR), Luxembourg
Representative
Name: Sean Sapcariu
Position: Programme Manager
Proxy
Name: Marie-Claude Marx
Position: Programme Manager
National Centre for Research and Development (NCBR), Poland
EJP RD JTC 2019: MoU
Representative
Name: Marcin Chmielewski
Position: Programme officer
The Foundation for Science and Technology (FCT), Portugal
Representative
Name: Anabela Isidro
Position: Science Officer
Proxy
Name: Rita Cavaleiro
Position: Science Officer
Slovak Academy of Sciences (SAS), Slovakia
Representative
Name: Jan Barancik, PhD
Position: Head, International Cooperation Dpt.
Proxy
Name: Zuzana Cernakova, PhD
Position: Programme officer
National Institute of Health Carlos III (ISCIII), Spain
Representative
Name: Rafael de Andrés Medina
Position: Head of the EU and Internationalization Division [EU+Int]
Proxy
Name: Ignacio Baanante
Position: Scientific Officer
Swedish Research Council (SRC), Sweden
Representative
Name: Malin Eklund
Position: Scientific officer
Vinnova, Sweden
Representative
Name: Frida Lundmark
Position: Scientific officer
EJP RD JTC 2019: MoU
Swiss National Science Foundation (SNSF), Switzerland
Representative
Name: Dr. Christoph Meier
Position: Scientific officer
The Netherlands Organisation for Health Research and Development
(ZonMw), The Netherlands
Representative
Name: Dr. Sonja van Weely
Position: Programme officer
Proxy
Name: Dr. Ir. Harald Moonen
Position: Programme Officer
The Scientific and Technological Research Council of Turkey (TUBITAK),
Turkey
Representative
Name: Dr. Jale Şahin
Position: Programme officier